up-to-date with a click!
Update June, 2017
 
Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.

The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Statin publications June 2017

Other

  1. Dujovne CA. Red yeast rice preparations: are they suitable substitutions for statins? Am J Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28601545
  2. Nathan DG. Cholesterol: the debate should be terminated. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2017; 31:2722-2728. http://www.ncbi.nlm.nih.gov/pubmed/?term=28663517
  3. Sanada S, Miyasaka Y, Kanno A et al. Efficacy of statin on vascular access patency in diabetic hemodialysis patients. The journal of vascular access 2017:0. http://www.ncbi.nlm.nih.gov/pubmed/?term=28604988
  4. Chang HY, Murimi I, Daubresse M et al. Effect of Direct-to-Consumer Advertising (DTCA) on Statin Use in the United States. Medical care 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28598891
  5. Ursoniu S, Mikhailidis DP, Serban MC et al. The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2017; 122:105-117. http://www.ncbi.nlm.nih.gov/pubmed/?term=28602797
  6. Vaidean GD, Vansal SS, Manczuk M. Television viewing time among statin users and non-users. The Polish Norwegian Study (PONS). Preventive medicine reports 2017; 7:106-109. http://www.ncbi.nlm.nih.gov/pubmed/?term=28626626

Add on treatments

  1. Ballantyne CM, Shah S, Sapre A et al. A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28624096
  2. Tani S, Nagao K, Kawauchi K et al. The Ratio of Eicosapentaenoic Acid (EPA) to Arachidonic Acid may be a Residual Risk Marker in Stable Coronary Artery Disease Patients Receiving Treatment with Statin Following EPA Therapy. Am J Cardiovasc Drugs 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28634822
  3. Chojnacki C, Blonska A, Chojnacki J. The Effects of Melatonin on Elevated Liver Enzymes during Statin Treatment. BioMed research international 2017; 2017:3204504. http://www.ncbi.nlm.nih.gov/pubmed/?term=28630863
  4. Ueda Y, Hiro T, Hirayama A et al. Effect of Ezetimibe on Stabilization and Regression of Intracoronary Plaque- The ZIPANGU Study. Circulation journal : official journal of the Japanese Circulation Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28592751
  5. Wang J, Ai XB, Wang F et al. Efficacy of ezetimibe combined with atorvastatin in treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International angiology : a journal of the International Union of Angiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28641407
  6. Bays HE, Patel MD, Mavros P et al. Real-world data to assess changes in low-density lipoprotein cholesterol and predicted cardiovascular risk after ezetimibe discontinuation post reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28647412
  7. Abdel Magid AM, Abbassi MM, Iskander EEM et al. Randomized comparative efficacy and safety study of intermittent simvastatin versus fenofibrate in hemodialysis. Journal of comparative effectiveness research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28627930
  8. Dai YY, Zhang HS, Zhang XG et al. Statin-ezetimibe versus statin lipid-lowering therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Thorac Dis 2017; 9:1345-1352. http://www.ncbi.nlm.nih.gov/pubmed/?term=28616287
  9. Zhang J, Long M, Yu Y. The effects of additional ezetimibe treatment to baseline rosuvastatin on circulating PCSK9 among patients with stable angina. J Thorac Dis 2017; 9:1226-1233. http://www.ncbi.nlm.nih.gov/pubmed/?term=28616272
  10. Sakamoto K, Kawamura M, Watanabe T et al. Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids Health Dis 2017; 16:122. http://www.ncbi.nlm.nih.gov/pubmed/?term=28646901
  11. Xu D, Hu J, Wu Q et al. Efficacy and safety of zhibitai in combination with atorvastatin for lipid lowering in patients with coronary heart disease. Oncotarget 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28611309 

Adherence

  1. McRae I, van Gool K, Hall J, Yen L. Role of Cost on Failure to Access Prescribed Pharmaceuticals: The Case of Statins. Applied health economics and health policy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28660496
  2. Guglielmi V, Bellia A, Pecchioli S et al. Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: A real-world evidence study in primary care. Atherosclerosis 2017; 263:36-41. http://www.ncbi.nlm.nih.gov/pubmed/?term=28599257
  3. Christie R, Sketris I, Andreou P et al. Does the Number of Pharmacies a Patient Frequents Affect Adherence to Statins? Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique 2017; 24:e20-e50. http://www.ncbi.nlm.nih.gov/pubmed/?term=28594479
  4. Lissaker CT, Wallert J, Held C, Olsson E. Emotional distress as a predictor of statin non-adherence among Swedish first-time myocardial infarction patients, 2006-2013. Journal of psychosomatic research 2017; 97:30-37. http://www.ncbi.nlm.nih.gov/pubmed/?term=28606496
  5. Volpp KG, Troxel AB, Mehta SJ et al. Effect of Electronic Reminders, Financial Incentives, and Social Support on Outcomes After Myocardial Infarction: The HeartStrong Randomized Clinical Trial. JAMA Intern Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28654972
  6. Flint AC, Conell C, Ren X et al. Statin Adherence Is Associated With Reduced Recurrent Stroke Risk in Patients With or Without Atrial Fibrillation. Stroke 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28596457

Atherosclerosis & Imaging

  1. Puri R, Ballantyne CM, Hoogeveen RC et al. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. Atherosclerosis 2017; 263:137-144. http://www.ncbi.nlm.nih.gov/pubmed/?term=28641153
  2. Sijbrands EJ. Xanthomas and atheromas. Atherosclerosis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28606368
  3. Ansheles AA, Rvacheva AV, Sergienko IV. Effect of Atorvastatin Therapy on the Level of CD34+CD133+CD309+ Endothelial Progenitor Cells in Patients with Coronary Heart Disease. Bulletin of experimental biology and medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28577105
  4. Ueda Y, Hiro T, Hirayama A et al. Effect of Ezetimibe on Stabilization and Regression of Intracoronary Plaque- The ZIPANGU Study. Circulation journal : official journal of the Japanese Circulation Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28592751
  5. Braamskamp M, Langslet G, McCrindle BW et al. Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children with Heterozygous Familial Hypercholesterolemia: The CHARON Study. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28592434
  6. Kulik A, Abreu AM, Boronat V, Ruel M. Intensive versus moderate atorvastatin therapy and one-year graft patency after CABG: Rationale and design of the ACTIVE (Aggressive Cholesterol Therapy to Inhibit Vein Graft Events) randomized controlled trial (NCT01528709). Contemporary clinical trials 2017; 59:98-104. http://www.ncbi.nlm.nih.gov/pubmed/?term=28611006
  7. Gili S, Iannaccone M, Colombo F et al. Effects of statins on plaque rupture assessed by optical coherence tomography in patients presenting with acute coronary syndromes: insights from the optical coherence tomography (OCT)-FORMIDABLE registry. European heart journal cardiovascular Imaging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28605473
  8. Kwan AC, Aronis KN, Sandfort V et al. Bridging the gap for lipid lowering therapy: plaque regression, coronary computed tomographic angiography, and imaging-guided personalized medicine. Expert Rev Cardiovasc Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28657444
  9. Wang J, Ai XB, Wang F et al. Efficacy of ezetimibe combined with atorvastatin in treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International angiology : a journal of the International Union of Angiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28641407
  10. Walus-Miarka M, Czarnecka D, Kloch-Badelek M et al. Carotid artery plaques - Are risk factors the same in men and women with familial hypercholesterolemia? Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28663044
  11. Janko M, Moore R, Kim AH et al. Carotid occlusion is associated with more frequent neurovascular events than moderately severe carotid stenosis. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28625670
  12. Blumenthal RS, Aslam MI, McEvoy JW. Using Trial Eligibility to Personalize Statin Therapy Appears No More Accurate Than a Coin Flip in Determining High-Risk Status. JACC. Cardiovascular imaging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28624410
  13. McClelland RL, Blaha MJ. Incorporating Coronary Artery Calcium Into Global Risk Scoring. JACC. Cardiovascular imaging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28624403
  14. Mortensen MB, Falk E, Li D et al. Statin Trials, Cardiovascular Events, and Coronary Artery Calcification: Implications for a Trial-Based Approach to Statin Therapy in MESA. JACC. Cardiovascular imaging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28624395
  15. Tan H, Zhou J, Yang X et al. 99mTc-labeled bevacizumab for detecting atherosclerotic plaque linked to plaque neovascularization and monitoring antiangiogenic effects of atorvastatin treatment in ApoE-/- mice. Scientific reports 2017; 7:3504. http://www.ncbi.nlm.nih.gov/pubmed/?term=28615707
  16. Hong JH, Sohn SI, Kwak J et al. Dose-Dependent Effect of Statin Pretreatment on Preventing the Periprocedural Complications of Carotid Artery Stenting. Stroke 2017; 48:1890-1894. http://www.ncbi.nlm.nih.gov/pubmed/?term=28626049

Atorvastatin/Rosuvastatin

  1. Puri R, Ballantyne CM, Hoogeveen RC et al. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. Atherosclerosis 2017; 263:137-144. http://www.ncbi.nlm.nih.gov/pubmed/?term=28641153
  2. Kim TE, Shin DS, Gu N et al. The Effect of Genetic Polymorphisms in SLCO2B1 on the Lipid-lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low-density Lipoprotein. Basic & clinical pharmacology & toxicology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28627804
  3. Kabel AM, Elkhoely AA. Targeting proinflammatory cytokines, oxidative stress, TGF-beta1 and STAT-3 by rosuvastatin and ubiquinone to ameliorate trastuzumab cardiotoxicity. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2017; 93:17-26. http://www.ncbi.nlm.nih.gov/pubmed/?term=28622591
  4. Chojnacki C, Blonska A, Chojnacki J. The Effects of Melatonin on Elevated Liver Enzymes during Statin Treatment. BioMed research international 2017; 2017:3204504. http://www.ncbi.nlm.nih.gov/pubmed/?term=28630863
  5. Zhang X, Zhou Y, Zhang S et al. Cerebral blood flow evaluation of intensive rosuvastatin therapy in stroke/transient ischemic attack patients with intracranial arterial atherosclerotic stenosis study: Rationale and design. Brain and behavior 2017; 7:e00689. http://www.ncbi.nlm.nih.gov/pubmed/?term=28638702
  6. Ansheles AA, Rvacheva AV, Sergienko IV. Effect of Atorvastatin Therapy on the Level of CD34+CD133+CD309+ Endothelial Progenitor Cells in Patients with Coronary Heart Disease. Bulletin of experimental biology and medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28577105
  7. Yang Y, Rong X, Lv X et al. Inhibition of mevalonate pathway prevents ischemia-induced cardiac dysfunction in rats via RhoA-independent signaling pathway. Cardiovasc Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28665545
  8. Braamskamp M, Langslet G, McCrindle BW et al. Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children with Heterozygous Familial Hypercholesterolemia: The CHARON Study. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28592434
  9. Mortensen MB, Budoff MJ, Li D et al. High Quality Statin Trials Support the 2013 ACC/AHA Cholesterol Guidelines After HOPE-3: The Multi-Ethnic Study of Atherosclerosis. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28634218
  10. Pagidipati NJ, Navar AM, Pieper KS et al. Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes: International Insights from the TECOS Trial. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28626088
  11. Lin Z, Jiang Z, Huang X et al. Preventive treatment with atorvastatin ameliorates endothelial dysfunction of small pulmonary arteries in monocrotaline-induced pulmonary hypertensive rats. Clinical and experimental hypertension (New York, N.Y. : 1993) 2017:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=28628347
  12. Li R, Barton HA. Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis. Clinical pharmacokinetics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28653144
  13. Kulik A, Abreu AM, Boronat V, Ruel M. Intensive versus moderate atorvastatin therapy and one-year graft patency after CABG: Rationale and design of the ACTIVE (Aggressive Cholesterol Therapy to Inhibit Vein Graft Events) randomized controlled trial (NCT01528709). Contemporary clinical trials 2017; 59:98-104. http://www.ncbi.nlm.nih.gov/pubmed/?term=28611006
  14. Mather JF, Corradi JP, Waszynski C et al. Statin and Its Association With Delirium in the Medical ICU. Critical care medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28622167
  15. Kokilambigai KS, Seetharaman R, Lakshmi KS. Critical review on the analytical techniques for the determination of the oldest statin-atorvastatin-in bulk, pharmaceutical formulations and biological fluids. Critical reviews in analytical chemistry 2017:0. http://www.ncbi.nlm.nih.gov/pubmed/?term=28644038
  16. Elmowafy M, Ibrahim HM, Ahmed MA et al. Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks. Drug delivery 2017; 24:932-941. http://www.ncbi.nlm.nih.gov/pubmed/?term=28617150
  17. Gidal BE, Mintzer S, Schwab M et al. Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters. Epilepsy research 2017; 135:64-70. http://www.ncbi.nlm.nih.gov/pubmed/?term=28624574
  18. Ishola IO, Tijani HK, Dosumu OO et al. Atorvastatin attenuates testosterone induced benign prostatic hyperplasia in rats: role of peroxisome proliferator activated receptor-gamma and cyclo-oxygenase-2. Fundamental & clinical pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28636803
  19. Sanchez M, Castiella A, Zapata E et al. Autoimmune Hepatitis (Immune-Mediated Liver Injury) Induced By Rosuvastatin. Gastroenterologia y hepatologia 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28655408
  20. Wang J, Ai XB, Wang F et al. Efficacy of ezetimibe combined with atorvastatin in treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International angiology : a journal of the International Union of Angiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28641407
  21. Roy S, Weinstock JL, Ishino AS et al. Association of Cognitive Impairment in Patients on 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitors. Journal of clinical medicine research 2017; 9:638-649. http://www.ncbi.nlm.nih.gov/pubmed/?term=28611866
  22. Kirzioglu FY, Tozum Bulut M, Dogan B et al. Anti-inflammatory effect of rosuvastatin decreases alveolar bone loss in experimental periodontitis. Journal of oral science 2017; 59:247-255. http://www.ncbi.nlm.nih.gov/pubmed/?term=28637984
  23. Dai YY, Zhang HS, Zhang XG et al. Statin-ezetimibe versus statin lipid-lowering therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Thorac Dis 2017; 9:1345-1352. http://www.ncbi.nlm.nih.gov/pubmed/?term=28616287
  24. Zhang J, Long M, Yu Y. The effects of additional ezetimibe treatment to baseline rosuvastatin on circulating PCSK9 among patients with stable angina. J Thorac Dis 2017; 9:1226-1233. http://www.ncbi.nlm.nih.gov/pubmed/?term=28616272
  25. Qiu S, Zhuo W, Sun C et al. Effects of atorvastatin on chronic subdural hematoma: A systematic review. Medicine (Baltimore) 2017; 96:e7290. http://www.ncbi.nlm.nih.gov/pubmed/?term=28658127
  26. Xu D, Hu J, Wu Q et al. Efficacy and safety of zhibitai in combination with atorvastatin for lipid lowering in patients with coronary heart disease. Oncotarget 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28611309
  27. Zhang K, Zhai S, Li K et al. Effect of Atorvastatin on lower extremity function of patients with hypertension and peripheral arterial disease. Pak J Pharm Sci 2017; 30:325-327. http://www.ncbi.nlm.nih.gov/pubmed/?term=28625961
  28. Akershoek JJ, Brouwer KM, Vlig M et al. Differential effects of Losartan and Atorvastatin in partial and full thickness burn wounds. PLoS One 2017; 12:e0179350. http://www.ncbi.nlm.nih.gov/pubmed/?term=28614412
  29. Tan H, Zhou J, Yang X et al. 99mTc-labeled bevacizumab for detecting atherosclerotic plaque linked to plaque neovascularization and monitoring antiangiogenic effects of atorvastatin treatment in ApoE-/- mice. Scientific reports 2017; 7:3504. http://www.ncbi.nlm.nih.gov/pubmed/?term=28615707
  30. Gossman W, Siddique M. Atorvastatin. In: StatPearls. Treasure Island (FL): StatPearls Publishing
  31. StatPearls Publishing LLC.; 2017.
  32. Hong JH, Sohn SI, Kwak J et al. Dose-Dependent Effect of Statin Pretreatment on Preventing the Periprocedural Complications of Carotid Artery Stenting. Stroke 2017; 48:1890-1894. http://www.ncbi.nlm.nih.gov/pubmed/?term=28626049

Basic science

  1. Gunjiganur Vemanaradhya G, Emani S, Mehta DS, Bhandari S. Effect of 1.2% of simvastatin gel as a local drug delivery system on Gingival Crevicular Fluid interleukin-6 & interleukin-8 levels in non surgical treatment of chronic periodontitis patients. Archives of oral biology 2017; 82:55-61. http://www.ncbi.nlm.nih.gov/pubmed/?term=28601733
  2. Lin CH, Hsu KW, Chen CH et al. Differential changes in the pharmacokinetics of statins in collagen-induced arthritis rats. Biochem Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28636885
  3. Taylor HS, Alderman M, D'Hooghe TM et al. Effect of Simvastatin on Baboon Endometriosis. Biology of reproduction 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28637327
  4. Pajohanfar NS, Mohebbi E, Hosseini-Bandegharaei A et al. Simvastatin prevents morphine-induced tolerance and dependence in mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2017; 93:406-411. http://www.ncbi.nlm.nih.gov/pubmed/?term=28654797
  5. Yang Y, Rong X, Lv X et al. Inhibition of mevalonate pathway prevents ischemia-induced cardiac dysfunction in rats via RhoA-independent signaling pathway. Cardiovasc Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28665545
  6. Lee YJ, Kim MJ, Yoon YS et al. Simvastatin treatment boosts benefits of apoptotic cell infusion in murine lung fibrosis. Cell death & disease 2017; 8:e2860. http://www.ncbi.nlm.nih.gov/pubmed/?term=28594406
  7. Fleige M, Glorius F. alpha-Unsubstituted Pyrroles by NHC-Catalyzed Three-Component Coupling - Direct Synthesis of a Versatile Atorvastatin Derivative. Chemistry (Weinheim an der Bergstrasse, Germany) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28666059
  8. Lin Z, Jiang Z, Huang X et al. Preventive treatment with atorvastatin ameliorates endothelial dysfunction of small pulmonary arteries in monocrotaline-induced pulmonary hypertensive rats. Clinical and experimental hypertension (New York, N.Y. : 1993) 2017:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=28628347
  9. Kokilambigai KS, Seetharaman R, Lakshmi KS. Critical review on the analytical techniques for the determination of the oldest statin-atorvastatin-in bulk, pharmaceutical formulations and biological fluids. Critical reviews in analytical chemistry 2017:0. http://www.ncbi.nlm.nih.gov/pubmed/?term=28644038
  10. Elmowafy M, Ibrahim HM, Ahmed MA et al. Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks. Drug delivery 2017; 24:932-941. http://www.ncbi.nlm.nih.gov/pubmed/?term=28617150
  11. Gidal BE, Mintzer S, Schwab M et al. Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters. Epilepsy research 2017; 135:64-70. http://www.ncbi.nlm.nih.gov/pubmed/?term=28624574
  12. Ishola IO, Tijani HK, Dosumu OO et al. Atorvastatin attenuates testosterone induced benign prostatic hyperplasia in rats: role of peroxisome proliferator activated receptor-gamma and cyclo-oxygenase-2. Fundamental & clinical pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28636803
  13. Mitsuhashi T, Uemoto R, Ishikawa K et al. Endothelial Nitric Oxide Synthase-Independent Pleiotropic Effects of Pitavastatin Against Atherogenesis and Limb Ischemia in Mice. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28592707
  14. Wilkinson EL, Sidaway JE, Cross MJ. Statin Regulated ERK5 Stimulates Tight Junction Formation and Reduces Permeability in Human Cardiac Endothelial Cells. Journal of cellular physiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28639275
  15. Wang L, Yao X, Li Q, Sun S. Effect of Simvastatin on Lipid Accumulation and the Expression of CXCL16 and Nephrin in Podocyte Induced by Oxidized LDL. Journal of investigative surgery : the official journal of the Academy of Surgical Research 2017:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28635512
  16. Kirzioglu FY, Tozum Bulut M, Dogan B et al. Anti-inflammatory effect of rosuvastatin decreases alveolar bone loss in experimental periodontitis. Journal of oral science 2017; 59:247-255. http://www.ncbi.nlm.nih.gov/pubmed/?term=28637984
  17. Basak S, Mondal S, Dey S et al. Fabrication of beta-cyclodextrin-mediated single bimolecular inclusion complex: characterization, molecular docking, in-vitro release and bioavailability studies for gefitinib and simvastatin conjugate. The Journal of pharmacy and pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28631808
  18. Huang X, Liang Y, Yang Y, Lu X. Single-step production of the simvastatin precursor monacolin J by engineering of an industrial Aspergillys terreus. Metabolic engineering 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28619444
  19. Fafilek B, Hampl M, Ricankova N et al. Statins do not inhibit the FGFR signaling in chondrocytes. Osteoarthritis and cartilage 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28583899
  20. Slupski W, Trocha M, Rutkowska M. Pharmacodynamic and pharmacokinetic interactions between simvastatin and diazepam in rats. Pharmacological reports : PR 2017; 69:943-952. http://www.ncbi.nlm.nih.gov/pubmed/?term=28666152
  21. Jarmuzek D, Pedzinski T, Hoffmann M et al. Experimental and theoretical studies on fluvastatin primary photoproduct formation. Physical chemistry chemical physics : PCCP 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28650504
  22. Ozkok E, Yorulmaz H, Ates G et al. The impact of pretreatment with simvastatin on kidney tissue of rats with acute sepsis. Physiology international 2017; 104:158-170. http://www.ncbi.nlm.nih.gov/pubmed/?term=28665194
  23. Tan H, Zhou J, Yang X et al. 99mTc-labeled bevacizumab for detecting atherosclerotic plaque linked to plaque neovascularization and monitoring antiangiogenic effects of atorvastatin treatment in ApoE-/- mice. Scientific reports 2017; 7:3504. http://www.ncbi.nlm.nih.gov/pubmed/?term=28615707
  24. Yu IC, Kuo PC, Yen JH et al. A Combination of Three Repurposed Drugs Administered at Reperfusion as a Promising Therapy for Postischemic Brain Injury. Translational stroke research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28624878
  25. Chu YT, Zhu XY, Zhang YY et al. [Hemostatic Effect of Spleen-invigorating, Qi-replenishing and Blood-containing Formula on Simvastatin-induced Zebrafish Hemorrhage Model]. Zhongguo shi yan xue ye xue za zhi 2017; 25:853-859. http://www.ncbi.nlm.nih.gov/pubmed/?term=28641649

Cancer

  1. E JY, Lu SE, Lin Y et al. Differential and joint effects of metformin and statins on overall survival of elderly patients with pancreatic adenocarcinoma: a large population-based study. Cancer Epidemiol Biomarkers Prev 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28619830
  2. Ishola IO, Tijani HK, Dosumu OO et al. Atorvastatin attenuates testosterone induced benign prostatic hyperplasia in rats: role of peroxisome proliferator aåctivated receptor-gamma and cyclo-oxygenase-2. Fundamental & clinical pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28636803
  3. Vogel TJ, Goodman MT, Li AJ, Jeon CY. Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer. Gynecologic oncology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28596017
  4. Song MK, Shin BS, Ha CS, Park WY. Would Lipophilic Statin Therapy as a Prognostic Factor Improve Survival in Patients With Uterine Cervical Cancer? International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28644162

Children

  1. Braamskamp M, Langslet G, McCrindle BW et al. Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children with Heterozygous Familial Hypercholesterolemia: The CHARON Study. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28592434

Cost-effectiveness

  1. McRae I, van Gool K, Hall J, Yen L. Role of Cost on Failure to Access Prescribed Pharmaceuticals: The Case of Statins. Applied health economics and health policy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28660496
  2. Seaman KL, Sanfilippo FM, Roughead EE et al. Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia. BMJ Open 2017; 7:e013691. http://www.ncbi.nlm.nih.gov/pubmed/?term=28637723
  3. Chapman SR, Fitzpatrick RW, Aladul MI. Has cost inhibited the uptake of more potent statins in England? Pharmacoepidemiol Drug Saf 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28612964

CVD

  1. Pagidipati NJ, Navar AM, Pieper KS et al. Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes: International Insights from the TECOS Trial. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28626088
  2. Schiele F, Ecarnot F, Chopard R. Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention. Eur J Prev Cardiol 2017; 24:88-100. http://www.ncbi.nlm.nih.gov/pubmed/?term=28618915
  3. Kjaergaard KA, Christiansen MK, Schmidt M et al. Long-Term Cardiovascular Risk in Heterozygous Familial Hypercholesterolemia Relatives Identified by Cascade Screening. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28652386
  4. Bays HE, Patel MD, Mavros P et al. Real-world data to assess changes in low-density lipoprotein cholesterol and predicted cardiovascular risk after ezetimibe discontinuation post reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28647412
  5. Hong YJ, Jeong MH, Bae JH et al. Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II. The Korean journal of internal medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28618772
  6. Sakamoto K, Kawamura M, Watanabe T et al. Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids Health Dis 2017; 16:122. http://www.ncbi.nlm.nih.gov/pubmed/?term=28646901
  7. Ursoniu S, Mikhailidis DP, Serban MC et al. The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2017; 122:105-117. http://www.ncbi.nlm.nih.gov/pubmed/?term=28602797
  8. Blackburn R, Osborn D, Walters K et al. Statin prescribing for prevention of cardiovascular disease amongst people with severe mental illness: Cohort study in UK primary care. Schizophrenia research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28599749

Endothelium/inflammation

  1. Kabel AM, Elkhoely AA. Targeting proinflammatory cytokines, oxidative stress, TGF-beta1 and STAT-3 by rosuvastatin and ubiquinone to ameliorate trastuzumab cardiotoxicity. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2017; 93:17-26. http://www.ncbi.nlm.nih.gov/pubmed/?term=28622591
  2. Ansheles AA, Rvacheva AV, Sergienko IV. Effect of Atorvastatin Therapy on the Level of CD34+CD133+CD309+ Endothelial Progenitor Cells in Patients with Coronary Heart Disease. Bulletin of experimental biology and medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28577105
  3. Wium-Andersen IK, Wium-Andersen MK, Jorgensen MB, Osler M. Anti-inflammatory treatment and risk for depression after first-time stroke in a cohort of 147 487 Danish patients. Journal of psychiatry & neuroscience : JPN 2017; 42:160244. http://www.ncbi.nlm.nih.gov/pubmed/?term=28632121
 

Ethnicity

  1. Fung CSC, Wan EYF, Chan AKC, Lam CLK. Statin use reduces cardiovascular events and all-cause mortality amongst Chinese patients with type 2 diabetes mellitus: a 5-year cohort study. BMC Cardiovasc Disord 2017; 17:166. http://www.ncbi.nlm.nih.gov/pubmed/?term=28645252
  2. Li R, Barton HA. Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis. Clinical pharmacokinetics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28653144

FH

  1. Bea AM, Perez-Calahorra S, Marco-Benedi V et al. Effect of intensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemia. Atherosclerosis 2017; 263:92-96. http://www.ncbi.nlm.nih.gov/pubmed/?term=28623742
  2. Braamskamp M, Langslet G, McCrindle BW et al. Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children with Heterozygous Familial Hypercholesterolemia: The CHARON Study. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28592434
  3. Pecin I, Hartgers ML, Hovingh GK et al. Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. Eur J Prev Cardiol 2017:2047487317717346. http://www.ncbi.nlm.nih.gov/pubmed/?term=28644091
  4. Walus-Miarka M, Czarnecka D, Kloch-Badelek M et al. Carotid artery plaques - Are risk factors the same in men and women with familial hypercholesterolemia? Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28663044
  5. Kjaergaard KA, Christiansen MK, Schmidt M et al. Long-Term Cardiovascular Risk in Heterozygous Familial Hypercholesterolemia Relatives Identified by Cascade Screening. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28652386

Genetics

  1. Kim TE, Shin DS, Gu N et al. The Effect of Genetic Polymorphisms in SLCO2B1 on the Lipid-lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low-density Lipoprotein. Basic & clinical pharmacology & toxicology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28627804
  2. Allen SC, Mamotte CD. Pleiotropic and Adverse Effects of Statins- Do Epigenetics Play a Role? J Pharmacol Exp Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28576976

Guidelines

  1. Waite LH, Phan YL, Spinler SA. Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. The Annals of pharmacotherapy 2017:1060028017714003. http://www.ncbi.nlm.nih.gov/pubmed/?term=28627235
  2. Mortensen MB, Budoff MJ, Li D et al. High Quality Statin Trials Support the 2013 ACC/AHA Cholesterol Guidelines After HOPE-3: The Multi-Ethnic Study of Atherosclerosis. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28634218
  3. Kwan AC, Aronis KN, Sandfort V et al. Bridging the gap for lipid lowering therapy: plaque regression, coronary computed tomographic angiography, and imaging-guided personalized medicine. Expert Rev Cardiovasc Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28657444
  4. Wong CJ, Inouye L. What's in a Number? Risk Thresholds in Different Statin Guidelines. Journal of general internal medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28664259
  5. Blumenthal RS, Aslam MI, McEvoy JW. Using Trial Eligibility to Personalize Statin Therapy Appears No More Accurate Than a Coin Flip in Determining High-Risk Status. JACC. Cardiovascular imaging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28624410
  6. McClelland RL, Blaha MJ. Incorporating Coronary Artery Calcium Into Global Risk Scoring. JACC. Cardiovascular imaging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28624403

LDL- related parameters

  1. Pinto X, Trias Vilagut F, Rius Taruella J, Mairal Sallan E. [Dyslipidemia management in patients with high cardiovascular risk in Spain. ALMA study]. Atencion primaria / Sociedad Espanola de Medicina de Familia y Comunitaria 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28619533
  2. Puri R, Ballantyne CM, Hoogeveen RC et al. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. Atherosclerosis 2017; 263:137-144. http://www.ncbi.nlm.nih.gov/pubmed/?term=28641153
  3. Schiele F, Ecarnot F, Chopard R. Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention. Eur J Prev Cardiol 2017; 24:88-100. http://www.ncbi.nlm.nih.gov/pubmed/?term=28618915
  4. Sinning D, Landmesser U. Effective low-density lipoprotein-lowering therapy: Implementation in clinical practice. Eur J Prev Cardiol 2017; 24:71-76. http://www.ncbi.nlm.nih.gov/pubmed/?term=28618905
  5. Hong YJ, Jeong MH, Bae JH et al. Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II. The Korean journal of internal medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28618772
  6. Sakamoto K, Kawamura M, Watanabe T et al. Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids Health Dis 2017; 16:122. http://www.ncbi.nlm.nih.gov/pubmed/?term=28646901
 Lifestyle
  1. Bahls M, Gross S, Ittermann T et al. Statins are related to impaired exercise capacity in males but not females. PLoS One 2017; 12:e0179534. http://www.ncbi.nlm.nih.gov/pubmed/?term=28617869

Meta-analyses

  1. Kamal S, Khan MA, Seth A et al. Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28585556
  2. Lin J, Liu H, Jiang J et al. Clinical evidence of efficacy of simvastatin for aneurysmal subarachnoid hemorrhage. J Int Med Res 2017:300060517713803. http://www.ncbi.nlm.nih.gov/pubmed/?term=28661267
  3. Qiu S, Zhuo W, Sun C et al. Effects of atorvastatin on chronic subdural hematoma: A systematic review. Medicine (Baltimore) 2017; 96:e7290. http://www.ncbi.nlm.nih.gov/pubmed/?term=28658127
  4. Ursoniu S, Mikhailidis DP, Serban MC et al. The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2017; 122:105-117. http://www.ncbi.nlm.nih.gov/pubmed/?term=28602797
  5. Suzumura EA, Ribeiro RA, Kawano-Dourado L et al. Effects of perioperative statin use on cardiovascular complications in patients submitted to non-cardiac surgery: protocol for a systematic review, meta-analysis, and trial sequential analysis. Systematic reviews 2017; 6:116. http://www.ncbi.nlm.nih.gov/pubmed/?term=28629445

Metabolic Syndrome - Diabetes

  1. Pagidipati NJ, Navar AM, Pieper KS et al. Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes: International Insights from the TECOS Trial. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28626088
  2. Olesen KKW, Madsen M, Egholm G et al. Patients With and Without Diabetes Without Significant Angiographic Coronary Artery Disease Have the Same Risk of Myocardial Infarction in a Real-World Population Receiving Appropriate Prophylactic Treatment. Diabetes Care 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28596210
  3. Sherling DH, Perumareddi P, Hennekens CH. Metabolic Syndrome. Journal of cardiovascular pharmacology and therapeutics 2017; 22:365-367. http://www.ncbi.nlm.nih.gov/pubmed/?term=28587579

New Treatments

  1. Ballantyne CM, Shah S, Sapre A et al. A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28624096
  2. Melendez QM, Krishnaji ST, Wooten CJ, Lopez D. Hypercholesterolemia: The role of PCSK9. Archives of biochemistry and biophysics 2017; 625-626:39-53. http://www.ncbi.nlm.nih.gov/pubmed/?term=28587771
  3. Bea AM, Perez-Calahorra S, Marco-Benedi V et al. Effect of intensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemia. Atherosclerosis 2017; 263:92-96. http://www.ncbi.nlm.nih.gov/pubmed/?term=28623742
  4. King P, Nicholls SJ. PCSK9 Inhibitors: Treating the Right Patients in Daily Practice. Current cardiology reports 2017; 19:66. http://www.ncbi.nlm.nih.gov/pubmed/?term=28643240
  5. Schreml J, Gouni-Berthold I. Role of anti-PCSK9 antibodies in the treatment of patients with statin intolerance. Curr Med Chem 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28618994
  6. Durairaj A, Sabates A, Nieves J et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data. Current treatment options in cardiovascular medicine 2017; 19:58. http://www.ncbi.nlm.nih.gov/pubmed/?term=28639183
  7. Pecin I, Hartgers ML, Hovingh GK et al. Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. Eur J Prev Cardiol 2017:2047487317717346. http://www.ncbi.nlm.nih.gov/pubmed/?term=28644091
  8. Schiele F, Ecarnot F, Chopard R. Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention. Eur J Prev Cardiol 2017; 24:88-100. http://www.ncbi.nlm.nih.gov/pubmed/?term=28618915
  9. Sinning D, Landmesser U. Effective low-density lipoprotein-lowering therapy: Implementation in clinical practice. Eur J Prev Cardiol 2017; 24:71-76. http://www.ncbi.nlm.nih.gov/pubmed/?term=28618905
  10. Zhang J, Long M, Yu Y. The effects of additional ezetimibe treatment to baseline rosuvastatin on circulating PCSK9 among patients with stable angina. J Thorac Dis 2017; 9:1226-1233. http://www.ncbi.nlm.nih.gov/pubmed/?term=28616272
  11. Teramoto T, Kondo A, Kiyosue A et al. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale. Lipids Health Dis 2017; 16:121. http://www.ncbi.nlm.nih.gov/pubmed/?term=28623954

PAD and statins

  1. Meltzer AJ, Sedrakyan A, Connolly PH et al. Risk factors for sub-optimal utilization of statins and antiplatelet therapy in patients undergoing revascularization for symptomatic peripheral arterial disease. Annals of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28602895
  2. Kitrou P, Katsanos K, Karnabatidis D et al. Current Evidence and future perspectives on Anti-Platelet and Statin Pharmacotherapy for Patients with Symptomatic Peripheral Arterial Disease. Current vascular pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28595535
  3. Zhang K, Zhai S, Li K et al. Effect of Atorvastatin on lower extremity function of patients with hypertension and peripheral arterial disease. Pak J Pharm Sci 2017; 30:325-327. http://www.ncbi.nlm.nih.gov/pubmed/?term=28625961

 Pleiotropic effects of statins

  1. Kamal S, Khan MA, Seth A et al. Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28585556
  2. Sapey E, Patel JM, Greenwood HL et al. Pulmonary Infections in the Elderly Lead to Impaired Neutrophil Targeting, Improved by Simvastatin. American journal of respiratory and critical care medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28657793
  3. Taylor HS, Alderman M, D'Hooghe TM et al. Effect of Simvastatin on Baboon Endometriosis. Biology of reproduction 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28637327
  4. Pajohanfar NS, Mohebbi E, Hosseini-Bandegharaei A et al. Simvastatin prevents morphine-induced tolerance and dependence in mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2017; 93:406-411. http://www.ncbi.nlm.nih.gov/pubmed/?term=28654797
  5. Lee YJ, Kim MJ, Yoon YS et al. Simvastatin treatment boosts benefits of apoptotic cell infusion in murine lung fibrosis. Cell death & disease 2017; 8:e2860. http://www.ncbi.nlm.nih.gov/pubmed/?term=28594406
  6. Batais MA, Khan AR, Bin Abdulhak AA. The Use of Statins and Risk of Community-Acquired Pneumonia. Current infectious disease reports 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28639080
  7. Mitsuhashi T, Uemoto R, Ishikawa K et al. Endothelial Nitric Oxide Synthase-Independent Pleiotropic Effects of Pitavastatin Against Atherogenesis and Limb Ischemia in Mice. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28592707
  8. Otsuka T, Mizuno K, Shinozaki T et al. Preventive effect of pravastatin on the development of hypertension in patients with hypercholesterolemia: A post-hoc analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28655522
  9. Tocci G, Presta V, Citoni B et al. Favourable impact of statin use on diastolic blood pressure levels: analysis of a large database of 24-hour ambulatory blood pressure monitoring. J Hypertens 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28582284
  10. Kirzioglu FY, Tozum Bulut M, Dogan B et al. Anti-inflammatory effect of rosuvastatin decreases alveolar bone loss in experimental periodontitis. Journal of oral science 2017; 59:247-255. http://www.ncbi.nlm.nih.gov/pubmed/?term=28637984
  11. Allen SC, Mamotte CD. Pleiotropic and Adverse Effects of Statins- Do Epigenetics Play a Role? J Pharmacol Exp Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28576976
  12. Watanabe T, Oku K, Amengual O et al. Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies. Lupus 2017:961203317716787. http://www.ncbi.nlm.nih.gov/pubmed/?term=28659045
  13. Saeedi Saravi SS, Saeedi Saravi SS, Arefidoust A, Dehpour AR. The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration. Metabolic brain disease 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28578514
  14. Ozkok E, Yorulmaz H, Ates G et al. The impact of pretreatment with simvastatin on kidney tissue of rats with acute sepsis. Physiology international 2017; 104:158-170. http://www.ncbi.nlm.nih.gov/pubmed/?term=28665194
  15. Suzumura EA, Ribeiro RA, Kawano-Dourado L et al. Effects of perioperative statin use on cardiovascular complications in patients submitted to non-cardiac surgery: protocol for a systematic review, meta-analysis, and trial sequential analysis. Systematic reviews 2017; 6:116. http://www.ncbi.nlm.nih.gov/pubmed/?term=28629445

Primary Prevention

  1. Kazi DS, Penko JM, Bibbins-Domingo K. Statins for Primary Prevention of Cardiovascular Disease: Review of Evidence and Recommendations for Clinical Practice. The Medical clinics of North America 2017; 101:689-699. http://www.ncbi.nlm.nih.gov/pubmed/?term=28577620

Registry data

  1. Richman JS, Graham LA, DeRussy A et al. Perioperative beta blockers and statins for noncardiac surgery patients with coronary stents. American journal of surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28641862
  2. Meltzer AJ, Sedrakyan A, Connolly PH et al. Risk factors for sub-optimal utilization of statins and antiplatelet therapy in patients undergoing revascularization for symptomatic peripheral arterial disease. Annals of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28602895
  3. Pinto X, Trias Vilagut F, Rius Taruella J, Mairal Sallan E. [Dyslipidemia management in patients with high cardiovascular risk in Spain. ALMA study]. Atencion primaria / Sociedad Espanola de Medicina de Familia y Comunitaria 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28619533
  4. Guglielmi V, Bellia A, Pecchioli S et al. Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: A real-world evidence study in primary care. Atherosclerosis 2017; 263:36-41. http://www.ncbi.nlm.nih.gov/pubmed/?term=28599257
  5. Fung CSC, Wan EYF, Chan AKC, Lam CLK. Statin use reduces cardiovascular events and all-cause mortality amongst Chinese patients with type 2 diabetes mellitus: a 5-year cohort study. BMC Cardiovasc Disord 2017; 17:166. http://www.ncbi.nlm.nih.gov/pubmed/?term=28645252
  6. Olesen KKW, Madsen M, Egholm G et al. Patients With and Without Diabetes Without Significant Angiographic Coronary Artery Disease Have the Same Risk of Myocardial Infarction in a Real-World Population Receiving Appropriate Prophylactic Treatment. Diabetes Care 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28596210
  7. Quinn KL, Macdonald EM, Mamdani MM et al. Lipophilic Statins and the Risk of Intracranial Hemorrhage Following Ischemic Stroke: A Population-Based Study. Drug Saf 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28620871
  8. Vogel TJ, Goodman MT, Li AJ, Jeon CY. Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer. Gynecologic oncology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28596017
  9. Kjaergaard KA, Christiansen MK, Schmidt M et al. Long-Term Cardiovascular Risk in Heterozygous Familial Hypercholesterolemia Relatives Identified by Cascade Screening. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28652386
  10. Bays HE, Patel MD, Mavros P et al. Real-world data to assess changes in low-density lipoprotein cholesterol and predicted cardiovascular risk after ezetimibe discontinuation post reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28647412
  11. Roy S, Weinstock JL, Ishino AS et al. Association of Cognitive Impairment in Patients on 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitors. Journal of clinical medicine research 2017; 9:638-649. http://www.ncbi.nlm.nih.gov/pubmed/?term=28611866
  12. Tocci G, Presta V, Citoni B et al. Favourable impact of statin use on diastolic blood pressure levels: analysis of a large database of 24-hour ambulatory blood pressure monitoring. J Hypertens 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28582284
  13. Wium-Andersen IK, Wium-Andersen MK, Jorgensen MB, Osler M. Anti-inflammatory treatment and risk for depression after first-time stroke in a cohort of 147 487 Danish patients. Journal of psychiatry & neuroscience : JPN 2017; 42:160244. http://www.ncbi.nlm.nih.gov/pubmed/?term=28632121
  14. Xu MX, Liu C, He YM et al. Long-term statin therapy could be efficacious in reducing the lipoprotein (a) levels in patients with coronary artery disease modified by some traditional risk factors. J Thorac Dis 2017; 9:1322-1332. http://www.ncbi.nlm.nih.gov/pubmed/?term=28616285
  15. Janko M, Moore R, Kim AH et al. Carotid occlusion is associated with more frequent neurovascular events than moderately severe carotid stenosis. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28625670
  16. Mortensen MB, Falk E, Li D et al. Statin Trials, Cardiovascular Events, and Coronary Artery Calcification: Implications for a Trial-Based Approach to Statin Therapy in MESA. JACC. Cardiovascular imaging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28624395
  17. Vaidean GD, Vansal SS, Manczuk M. Television viewing time among statin users and non-users. The Polish Norwegian Study (PONS). Preventive medicine reports 2017; 7:106-109. http://www.ncbi.nlm.nih.gov/pubmed/?term=28626626
  18. Blackburn R, Osborn D, Walters K et al. Statin prescribing for prevention of cardiovascular disease amongst people with severe mental illness: Cohort study in UK primary care. Schizophrenia research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28599749
  19. Flint AC, Conell C, Ren X et al. Statin Adherence Is Associated With Reduced Recurrent Stroke Risk in Patients With or Without Atrial Fibrillation. Stroke 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28596457
  20. Siddiqui FM, Langefeld CD, Moomaw CJ et al. Use of Statins and Outcomes in Intracerebral Hemorrhage Patients. Stroke 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28663510

Renal Disease

  1. Nash DM, Brimble S, Markle-Reid M et al. Quality of Care for Patients With Chronic Kidney Disease in the Primary Care Setting: A Retrospective Cohort Study From Ontario, Canada. Canadian journal of kidney health and disease 2017; 4:2054358117703059. http://www.ncbi.nlm.nih.gov/pubmed/?term=28616249
  2. Abdel Magid AM, Abbassi MM, Iskander EEM et al. Randomized comparative efficacy and safety study of intermittent simvastatin versus fenofibrate in hemodialysis. Journal of comparative effectiveness research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28627930
  3. Ozkok E, Yorulmaz H, Ates G et al. The impact of pretreatment with simvastatin on kidney tissue of rats with acute sepsis. Physiology international 2017; 104:158-170. http://www.ncbi.nlm.nih.gov/pubmed/?term=28665194
  4. Heine GH, Rogacev KS, Weingartner O, Marsche G. Still a reasonable goal: Targeting cholesterol in dialysis and advanced chronic kidney disease patients. Semin Dial 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28628255 

Reviews

  1. Waite LH, Phan YL, Spinler SA. Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. The Annals of pharmacotherapy 2017:1060028017714003. http://www.ncbi.nlm.nih.gov/pubmed/?term=28627235
  2. Melendez QM, Krishnaji ST, Wooten CJ, Lopez D. Hypercholesterolemia: The role of PCSK9. Archives of biochemistry and biophysics 2017; 625-626:39-53. http://www.ncbi.nlm.nih.gov/pubmed/?term=28587771
  3. King P, Nicholls SJ. PCSK9 Inhibitors: Treating the Right Patients in Daily Practice. Current cardiology reports 2017; 19:66. http://www.ncbi.nlm.nih.gov/pubmed/?term=28643240
  4. Batais MA, Khan AR, Bin Abdulhak AA. The Use of Statins and Risk of Community-Acquired Pneumonia. Current infectious disease reports 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28639080
  5. Schreml J, Gouni-Berthold I. Role of anti-PCSK9 antibodies in the treatment of patients with statin intolerance. Curr Med Chem 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28618994
  6. Durairaj A, Sabates A, Nieves J et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data. Current treatment options in cardiovascular medicine 2017; 19:58. http://www.ncbi.nlm.nih.gov/pubmed/?term=28639183
  7. Kitrou P, Katsanos K, Karnabatidis D et al. Current Evidence and future perspectives on Anti-Platelet and Statin Pharmacotherapy for Patients with Symptomatic Peripheral Arterial Disease. Current vascular pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28595535
  8. Pecin I, Hartgers ML, Hovingh GK et al. Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. Eur J Prev Cardiol 2017:2047487317717346. http://www.ncbi.nlm.nih.gov/pubmed/?term=28644091
  9. Schiele F, Ecarnot F, Chopard R. Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention. Eur J Prev Cardiol 2017; 24:88-100. http://www.ncbi.nlm.nih.gov/pubmed/?term=28618915
  10. Sinning D, Landmesser U. Effective low-density lipoprotein-lowering therapy: Implementation in clinical practice. Eur J Prev Cardiol 2017; 24:71-76. http://www.ncbi.nlm.nih.gov/pubmed/?term=28618905
  11. Kwan AC, Aronis KN, Sandfort V et al. Bridging the gap for lipid lowering therapy: plaque regression, coronary computed tomographic angiography, and imaging-guided personalized medicine. Expert Rev Cardiovasc Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28657444
  12. Yu Q, Chen Y, Xu CB. Statins and New-Onset Diabetes Mellitus: LDL Receptor May Provide a Key Link. Frontiers in pharmacology 2017; 8:372. http://www.ncbi.nlm.nih.gov/pubmed/?term=28659805
  13. Sherling DH, Perumareddi P, Hennekens CH. Metabolic Syndrome. Journal of cardiovascular pharmacology and therapeutics 2017; 22:365-367. http://www.ncbi.nlm.nih.gov/pubmed/?term=28587579
  14. Wong CJ, Inouye L. What's in a Number? Risk Thresholds in Different Statin Guidelines. Journal of general internal medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28664259
  15. Allen SC, Mamotte CD. Pleiotropic and Adverse Effects of Statins- Do Epigenetics Play a Role? J Pharmacol Exp Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28576976
  16. Filippi M, Rocca MA. Simvastatin and cognition in multiple sclerosis. Lancet neurology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28600188
  17. Kazi DS, Penko JM, Bibbins-Domingo K. Statins for Primary Prevention of Cardiovascular Disease: Review of Evidence and Recommendations for Clinical Practice. The Medical clinics of North America 2017; 101:689-699. http://www.ncbi.nlm.nih.gov/pubmed/?term=28577620
  18. Saeedi Saravi SS, Saeedi Saravi SS, Arefidoust A, Dehpour AR. The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration. Metabolic brain disease 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28578514
  19. Stoekenbroek RM, Kastelein JJP. Dyslipidaemia: Statin-associated muscle symptoms - really all in the mind? Nat Rev Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28631752
  20. Guemara R, Lazarou I, Guerne IA. Drug-induced myopathies. Revue medicale suisse 2017; 13:1013-1017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28627846
  21. Heine GH, Rogacev KS, Weingartner O, Marsche G. Still a reasonable goal: Targeting cholesterol in dialysis and advanced chronic kidney disease patients. Semin Dial 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28628255
  22. Doyle M, Bhimji S. Statin Medications. In: StatPearls. Treasure Island (FL): StatPearls Publishing. StatPearls Publishing LLC.; 2017.
  23. Gossman W, Bhimji S. Fluvastatin. In: StatPearls. Treasure Island (FL): StatPearls Publishing. StatPearls Publishing LLC.; 2017.
  24. Gossman W, Siddique M. Atorvastatin. In: StatPearls. Treasure Island (FL): StatPearls Publishing. StatPearls Publishing LLC.; 2017.

Safety and side effects

  1. Mezian K, Vacek J, Navratil L, Ozcakar L. Bilateral Rectus Femoris Muscle Rupture Following Statin Medication. American journal of physical medicine & rehabilitation 2017; 96:e138. http://www.ncbi.nlm.nih.gov/pubmed/?term=28628543
  2. Chojnacki C, Blonska A, Chojnacki J. The Effects of Melatonin on Elevated Liver Enzymes during Statin Treatment. BioMed research international 2017; 2017:3204504. http://www.ncbi.nlm.nih.gov/pubmed/?term=28630863
  3. de Kanter R, Kohl C. Letter to the Editor, Physiologically based pharmacokinetic predictions of intestinal BCRP-mediated effect of telmisartan on the pharmacokinetics of rosuvastatin in humans. Biopharmaceutics & drug disposition 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28656708
  4. Yim DS. Author's response to letter to the editor on: Physiologically based pharmacokinetic predictions of intestinal BCRP-mediated effect of telmisartan on the pharmacokinetics of rosuvastatin in humans. Biopharmaceutics & drug disposition 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28656677
  5. Shun-Shin MJ, Francis DP. Is this muscle pain caused by my statin? Bmj 2017; 357:j3030. http://www.ncbi.nlm.nih.gov/pubmed/?term=28645927
  6. Hussenbux A, Hofer M, Steuer A. Statin-induced necrotizing autoimmune myopathy: importance of early recognition. British journal of hospital medicine (London, England : 2005) 2017; 78:352-353. http://www.ncbi.nlm.nih.gov/pubmed/?term=28614015
  7. Banakh I, Haji K, Kung R et al. Severe Rhabdomyolysis due to Presumed Drug Interactions between Atorvastatin with Amlodipine and Ticagrelor. Case reports in critical care 2017; 2017:3801819. http://www.ncbi.nlm.nih.gov/pubmed/?term=28630772
  8. Li R, Barton HA. Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis. Clinical pharmacokinetics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28653144
  9. Schreml J, Gouni-Berthold I. Role of anti-PCSK9 antibodies in the treatment of patients with statin intolerance. Curr Med Chem 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28618994
  10. Quinn KL, Macdonald EM, Mamdani MM et al. Lipophilic Statins and the Risk of Intracranial Hemorrhage Following Ischemic Stroke: A Population-Based Study. Drug Saf 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28620871
  11. Gidal BE, Mintzer S, Schwab M et al. Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters. Epilepsy research 2017; 135:64-70. http://www.ncbi.nlm.nih.gov/pubmed/?term=28624574
  12. Yu Q, Chen Y, Xu CB. Statins and New-Onset Diabetes Mellitus: LDL Receptor May Provide a Key Link. Frontiers in pharmacology 2017; 8:372. http://www.ncbi.nlm.nih.gov/pubmed/?term=28659805
  13. Sanchez M, Castiella A, Zapata E et al. Autoimmune Hepatitis (Immune-Mediated Liver Injury) Induced By Rosuvastatin. Gastroenterologia y hepatologia 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28655408
  14. Santos TRA, Silveira EA, Pereira LV et al. Potential drug-drug interactions in older adults: A population-based study. Geriatrics & gerontology international 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28635169
  15. Sahebkar A, Banach M. Response letter: Management of statin-induced myopathies: Much demands and still (almost) empty hands! Journal of cachexia, sarcopenia and muscle 2017; 8:514-515. http://www.ncbi.nlm.nih.gov/pubmed/?term=28631417
  16. Slomski A. Nocebo Effect May Account for Statin Adverse Events. Jama 2017; 317:2476. http://www.ncbi.nlm.nih.gov/pubmed/?term=28655010
  17. Stoekenbroek RM, Kastelein JJP. Dyslipidaemia: Statin-associated muscle symptoms - really all in the mind? Nat Rev Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28631752
  18. Teutonico A, Libutti P, Lomonte C, Basile C. Simvastatin-induced myoglobinuric acute kidney injury following ciclosporin treatment for alopecia universalis. NDT plus 2010; 3:273-275. http://www.ncbi.nlm.nih.gov/pubmed/?term=28657046
  19. Slupski W, Trocha M, Rutkowska M. Pharmacodynamic and pharmacokinetic interactions between simvastatin and diazepam in rats. Pharmacological reports : PR 2017; 69:943-952. http://www.ncbi.nlm.nih.gov/pubmed/?term=28666152
  20. Bahls M, Gross S, Ittermann T et al. Statins are related to impaired exercise capacity in males but not females. PLoS One 2017; 12:e0179534. http://www.ncbi.nlm.nih.gov/pubmed/?term=28617869
  21. Guemara R, Lazarou I, Guerne IA. Drug-induced myopathies. Revue medicale suisse 2017; 13:1013-1017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28627846

Stroke and CNS

  1. Zhang X, Zhou Y, Zhang S et al. Cerebral blood flow evaluation of intensive rosuvastatin therapy in stroke/transient ischemic attack patients with intracranial arterial atherosclerotic stenosis study: Rationale and design. Brain and behavior 2017; 7:e00689. http://www.ncbi.nlm.nih.gov/pubmed/?term=28638702
  2. Mather JF, Corradi JP, Waszynski C et al. Statin and Its Association With Delirium in the Medical ICU. Critical care medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28622167
  3. Quinn KL, Macdonald EM, Mamdani MM et al. Lipophilic Statins and the Risk of Intracranial Hemorrhage Following Ischemic Stroke: A Population-Based Study. Drug Saf 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28620871
  4. Roy S, Weinstock JL, Ishino AS et al. Association of Cognitive Impairment in Patients on 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitors. Journal of clinical medicine research 2017; 9:638-649. http://www.ncbi.nlm.nih.gov/pubmed/?term=28611866
  5. Lin J, Liu H, Jiang J et al. Clinical evidence of efficacy of simvastatin for aneurysmal subarachnoid hemorrhage. J Int Med Res 2017:300060517713803. http://www.ncbi.nlm.nih.gov/pubmed/?term=28661267
  6. Wium-Andersen IK, Wium-Andersen MK, Jorgensen MB, Osler M. Anti-inflammatory treatment and risk for depression after first-time stroke in a cohort of 147 487 Danish patients. Journal of psychiatry & neuroscience : JPN 2017; 42:160244. http://www.ncbi.nlm.nih.gov/pubmed/?term=28632121
  7. Janko M, Moore R, Kim AH et al. Carotid occlusion is associated with more frequent neurovascular events than moderately severe carotid stenosis. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28625670
  8. Chan D, Binks S, Nicholas JM et al. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. Lancet neurology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28600189
  9. Filippi M, Rocca MA. Simvastatin and cognition in multiple sclerosis. Lancet neurology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28600188
  10. Qiu S, Zhuo W, Sun C et al. Effects of atorvastatin on chronic subdural hematoma: A systematic review. Medicine (Baltimore) 2017; 96:e7290. http://www.ncbi.nlm.nih.gov/pubmed/?term=28658127
  11. Saeedi Saravi SS, Saeedi Saravi SS, Arefidoust A, Dehpour AR. The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration. Metabolic brain disease 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28578514
  12. Flint AC, Conell C, Ren X et al. Statin Adherence Is Associated With Reduced Recurrent Stroke Risk in Patients With or Without Atrial Fibrillation. Stroke 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28596457
  13. Hong JH, Sohn SI, Kwak J et al. Dose-Dependent Effect of Statin Pretreatment on Preventing the Periprocedural Complications of Carotid Artery Stenting. Stroke 2017; 48:1890-1894. http://www.ncbi.nlm.nih.gov/pubmed/?term=28626049
  14. Siddiqui FM, Langefeld CD, Moomaw CJ et al. Use of Statins and Outcomes in Intracerebral Hemorrhage Patients. Stroke 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28663510

Triglycerides/HDL

  1. Xu MX, Liu C, He YM et al. Long-term statin therapy could be efficacious in reducing the lipoprotein (a) levels in patients with coronary artery disease modified by some traditional risk factors. J Thorac Dis 2017; 9:1322-1332. http://www.ncbi.nlm.nih.gov/pubmed/?term=28616285

Trials

  1. Ballantyne CM, Shah S, Sapre A et al. A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28624096
  2. Tani S, Nagao K, Kawauchi K et al. The Ratio of Eicosapentaenoic Acid (EPA) to Arachidonic Acid may be a Residual Risk Marker in Stable Coronary Artery Disease Patients Receiving Treatment with Statin Following EPA Therapy. Am J Cardiovasc Drugs 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28634822
  3. Sapey E, Patel JM, Greenwood HL et al. Pulmonary Infections in the Elderly Lead to Impaired Neutrophil Targeting, Improved by Simvastatin. American journal of respiratory and critical care medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28657793
  4. Puri R, Ballantyne CM, Hoogeveen RC et al. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. Atherosclerosis 2017; 263:137-144. http://www.ncbi.nlm.nih.gov/pubmed/?term=28641153
  5. Kim TE, Shin DS, Gu N et al. The Effect of Genetic Polymorphisms in SLCO2B1 on the Lipid-lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low-density Lipoprotein. Basic & clinical pharmacology & toxicology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28627804
  6. Fung CSC, Wan EYF, Chan AKC, Lam CLK. Statin use reduces cardiovascular events and all-cause mortality amongst Chinese patients with type 2 diabetes mellitus: a 5-year cohort study. BMC Cardiovasc Disord 2017; 17:166. http://www.ncbi.nlm.nih.gov/pubmed/?term=28645252
  7. Zhang X, Zhou Y, Zhang S et al. Cerebral blood flow evaluation of intensive rosuvastatin therapy in stroke/transient ischemic attack patients with intracranial arterial atherosclerotic stenosis study: Rationale and design. Brain and behavior 2017; 7:e00689. http://www.ncbi.nlm.nih.gov/pubmed/?term=28638702
  8. Ansheles AA, Rvacheva AV, Sergienko IV. Effect of Atorvastatin Therapy on the Level of CD34+CD133+CD309+ Endothelial Progenitor Cells in Patients with Coronary Heart Disease. Bulletin of experimental biology and medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28577105
  9. Ueda Y, Hiro T, Hirayama A et al. Effect of Ezetimibe on Stabilization and Regression of Intracoronary Plaque- The ZIPANGU Study. Circulation journal : official journal of the Japanese Circulation Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28592751
  10. Braamskamp M, Langslet G, McCrindle BW et al. Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children with Heterozygous Familial Hypercholesterolemia: The CHARON Study. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28592434
  11. Pagidipati NJ, Navar AM, Pieper KS et al. Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes: International Insights from the TECOS Trial. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28626088
  12. Kulik A, Abreu AM, Boronat V, Ruel M. Intensive versus moderate atorvastatin therapy and one-year graft patency after CABG: Rationale and design of the ACTIVE (Aggressive Cholesterol Therapy to Inhibit Vein Graft Events) randomized controlled trial (NCT01528709). Contemporary clinical trials 2017; 59:98-104. http://www.ncbi.nlm.nih.gov/pubmed/?term=28611006
  13. Gili S, Iannaccone M, Colombo F et al. Effects of statins on plaque rupture assessed by optical coherence tomography in patients presenting with acute coronary syndromes: insights from the optical coherence tomography (OCT)-FORMIDABLE registry. European heart journal cardiovascular Imaging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28605473
  14. Wang J, Ai XB, Wang F et al. Efficacy of ezetimibe combined with atorvastatin in treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. International angiology : a journal of the International Union of Angiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28641407
  15. Song MK, Shin BS, Ha CS, Park WY. Would Lipophilic Statin Therapy as a Prognostic Factor Improve Survival in Patients With Uterine Cervical Cancer? International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28644162
  16. Otsuka T, Mizuno K, Shinozaki T et al. Preventive effect of pravastatin on the development of hypertension in patients with hypercholesterolemia: A post-hoc analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28655522
  17. Abdel Magid AM, Abbassi MM, Iskander EEM et al. Randomized comparative efficacy and safety study of intermittent simvastatin versus fenofibrate in hemodialysis. Journal of comparative effectiveness research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28627930
  18. Dai YY, Zhang HS, Zhang XG et al. Statin-ezetimibe versus statin lipid-lowering therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Thorac Dis 2017; 9:1345-1352. http://www.ncbi.nlm.nih.gov/pubmed/?term=28616287
  19. Zhang J, Long M, Yu Y. The effects of additional ezetimibe treatment to baseline rosuvastatin on circulating PCSK9 among patients with stable angina. J Thorac Dis 2017; 9:1226-1233. http://www.ncbi.nlm.nih.gov/pubmed/?term=28616272
  20. Sanada S, Miyasaka Y, Kanno A et al. Efficacy of statin on vascular access patency in diabetic hemodialysis patients. The journal of vascular access 2017:0. http://www.ncbi.nlm.nih.gov/pubmed/?term=28604988
  21. Volpp KG, Troxel AB, Mehta SJ et al. Effect of Electronic Reminders, Financial Incentives, and Social Support on Outcomes After Myocardial Infarction: The HeartStrong Randomized Clinical Trial. JAMA Intern Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28654972
  22. Hong YJ, Jeong MH, Bae JH et al. Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II. The Korean journal of internal medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28618772
  23. Chan D, Binks S, Nicholas JM et al. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. Lancet neurology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28600189
  24. Sakamoto K, Kawamura M, Watanabe T et al. Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids Health Dis 2017; 16:122. http://www.ncbi.nlm.nih.gov/pubmed/?term=28646901
  25. Teramoto T, Kondo A, Kiyosue A et al. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale. Lipids Health Dis 2017; 16:121. http://www.ncbi.nlm.nih.gov/pubmed/?term=28623954
  26. Watanabe T, Oku K, Amengual O et al. Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies. Lupus 2017:961203317716787. http://www.ncbi.nlm.nih.gov/pubmed/?term=28659045
  27. Xu D, Hu J, Wu Q et al. Efficacy and safety of zhibitai in combination with atorvastatin for lipid lowering in patients with coronary heart disease. Oncotarget 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28611309
  28. Zhang K, Zhai S, Li K et al. Effect of Atorvastatin on lower extremity function of patients with hypertension and peripheral arterial disease. Pak J Pharm Sci 2017; 30:325-327. http://www.ncbi.nlm.nih.gov/pubmed/?term=28625961
  29. Hong JH, Sohn SI, Kwak J et al. Dose-Dependent Effect of Statin Pretreatment on Preventing the Periprocedural Complications of Carotid Artery Stenting. Stroke 2017; 48:1890-1894. http://www.ncbi.nlm.nih.gov/pubmed/?term=28626049
 Women and elderly
  1. Sapey E, Patel JM, Greenwood HL et al. Pulmonary Infections in the Elderly Lead to Impaired Neutrophil Targeting, Improved by Simvastatin. American journal of respiratory and critical care medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28657793
  2. Santos TRA, Silveira EA, Pereira LV et al. Potential drug-drug interactions in older adults: A population-based study. Geriatrics & gerontology international 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28635169

Twitter
IAS Website
For information
You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.
 
This activity is supported by an educational grant from Pfizer.